Skip to main content
HEM Pharma Inc. logo

HEM Pharma Inc. — Investor Relations & Filings

Ticker · 376270 ISIN · KR7376270005 KO Manufacturing
Open in API
Filings indexed 94 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country KR South Korea
Listing KO 376270

About HEM Pharma Inc.

https://hempharma.bio/

HEM Pharma Inc. is a biotechnology company specializing in microbiome-based healthcare solutions. The company researches and develops Live Biotherapeutic Products (LBPs), health functional foods, and other bio-products derived from human-effective microbes. A core component of its R&D is the proprietary Pharmaceutical Meta-Analysis System (PMAS), a technology platform that simulates the human gut microbiome to screen for and analyze beneficial microorganisms. In addition to its product pipeline, HEM Pharma provides personalized healthcare services based on microbiome analysis and offers Contract Development and Manufacturing Organization (CDMO) services for next-generation biological materials.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a detailed ‘‘주식등의 대량보유상황보고서 (일반)’’ – a large shareholding status report filed under Korea’s Capital Markets and Financial Investment Business Act, disclosing changes in ownership percentages, pledge/trust arrangements, insider and related-party holdings, and material threshold crossings. This corresponds exactly to a Major Shareholding Notification. No other category (e.g., proxy, dividend, earnings) fits the content.
2026-04-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is an “임원·주요주주 특정증권등 소유상황보고서” filed with the Securities and Futures Commission and Korea Exchange, detailing an officer’s share ownership and changes (including a share disposal due to resignation). This matches the definition of a director’s personal share transaction report (insider dealing).
2026-04-06 Korean
[기재정정]주요사항보고서(회사분할결정)
Regulatory Filings Classification · 1% confidence The document is a Korean “주요사항보고서” (major fact report) filed with the Financial Services Commission and Korea Exchange, specifically an amendment (“정정신고”) concerning a previously announced corporate spin‐off decision that was later halted after a shareholder vote. It is neither an annual or interim financial report, earnings release, nor investor presentation. It is not announcing a dividend, board change, M&A, or share issuance but is a mandated regulatory disclosure. Under the provided taxonomy, it best fits the general "Regulatory Filings" fallback category (RNS).
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory notification detailing the appointment, dismissal, or mid-term resignation of outside directors (‘사외이사’). It provides specific names, dates, and roles for board changes rather than reporting financials or voting outcomes. This exactly matches the ‘Board/Management Information’ category, which covers announcements of changes in the company's board of directors or senior management.
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and provides detailed voting outcomes for each agenda item, including vote counts, approval rates, and resolutions passed or failed. It is not the full annual report nor an announcement of an upcoming meeting but rather the declaration of voting results. Therefore it matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.